Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BB Biotech ( (CH:BION) ) is now available.
BB Biotech AG has released its interim report for the first half of 2025, revealing a loss of CHF 341 million, a significant decline from the CHF 173 million profit reported in the same period last year. This downturn reflects the stock price performance of the companies within its investment portfolio, indicating potential challenges in the biotechnology investment landscape.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is an investment company based in Schaffhausen, Switzerland, and is listed on the Swiss and German stock exchanges. Since 1993, the company has focused on investing in innovative drug development companies primarily located in the USA and Western Europe. BB Biotech AG is recognized as a leading investor in the biotechnology sector, guided by a knowledgeable board of directors and an experienced investment management team from Bellevue Asset Management AG.
Average Trading Volume: 77,858
Technical Sentiment Signal: Sell
Current Market Cap: CHF1.76B
See more data about BION stock on TipRanks’ Stock Analysis page.